Dimensional Fund Advisors LP Has $1.14 Billion Stake in Bristol Myers Squibb Company $BMY

Dimensional Fund Advisors LP lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 2.9% during the first quarter, HoldingsChannel.com reports. The fund owned 18,762,589 shares of the biopharmaceutical company’s stock after purchasing an additional 520,330 shares during the period. Dimensional Fund Advisors LP’s holdings in Bristol Myers Squibb were worth $1,137,847,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BMY. waypoint wealth counsel bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $1,194,000. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb in the 4th quarter valued at $34,406,000. Axxcess Wealth Management LLC boosted its stake in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares during the period. Daytona Street Capital LLC acquired a new position in Bristol Myers Squibb in the 4th quarter worth $1,362,000. Finally, Pensionfund Sabic bought a new position in Bristol Myers Squibb during the 4th quarter worth about $1,845,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $60.71 on Monday. The stock has a market capitalization of $123.97 billion, a PE ratio of 17.05, a P/E/G ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The firm has a fifty day simple moving average of $57.02 and a 200 day simple moving average of $57.80. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY.
• Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself.
• Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability.

Analysts Set New Price Targets

A number of analysts have recently commented on BMY shares. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Cantor Fitzgerald reiterated a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Bank of America dropped their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $61.25.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.